Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Duobrii Clear all
Not listed Phase 1Phase 2 Interventional

A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118

NCT01670513
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-118 Low Strength, IDP-118 High Strength
Drug
Lead sponsor
Dow Pharmaceutical Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Santa Rosa, California • Clinton Township, Michigan • Fort Gratiot, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis

NCT02785159
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-118 Lotion, Tazorac Cream, IDP-118 Vehicle Lotion, IDP-118 Vehicle Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
14
States / cities
Encino, California • Orange Park, Florida • Pinellas Park, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Results available

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

NCT04720105
View directory record Official record
Conditions
Palmoplantar Psoriasis, Plaque Psoriasis
Interventions
Duobrii®
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

NCT02462122
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-118 Lotion, IDP-118 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Fremont, California • Boynton Beach, Florida • North Miami Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis

NCT02462083
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-118 Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
46
States / cities
Mobile, Alabama • Beverly Hills, California • Encinitas, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis

NCT02785172
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-118 Vehicle Lotion, IDP-118 Vehicle Cream, IDP-118 Lotion, Ultravate Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
14
States / cities
Fullerton, California • La Mesa, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

NCT06042647
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
0.01% Halobetasol, 0.045% Tazarotene, 0.05% Clobetasol Propionate
Drug
Lead sponsor
Dermatology Consulting Services, PLLC
Network
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 3 Interventional

Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults

NCT05203315
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Duobrii 0.01 % / 0.045 % Topical Lotion, CeraVe, Topical Cream
Drug
Lead sponsor
Austin Institute for Clinical Research
Network
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Houston, Texas • Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 4 Interventional

A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis

NCT03988439
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-118 Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Doral, Florida • Miami, Florida • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 6, 2026, 5:19 AM EDT
Terminated Phase 3 Interventional Results available

Duobrii Treatment of Acne Keloidalis Nuchae (AKN)

NCT05608499
View directory record Official record
Conditions
Acne Keloidalis Nuchae, AKN
Interventions
Duobrii, Placebo, Bryhali
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 6, 2026, 5:19 AM EDT
Recruiting Phase 4 Interventional

Duobrii in Combination With Biologics

NCT04119102
View directory record Official record
Conditions
Psoriasis
Interventions
Duobrii
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

NCT02045277
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-118 Lotion, IDP-118 Monad HP Lotion, IDP-118 Monad Taz Lotion, IDP-118 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
18
States / cities
Encino, California • San Diego, California • Santa Rosa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.

NCT05282771
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%, Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

NCT02462070
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-118 Lotion, IDP-118 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Mobile, Alabama • Beverly Hills, California • Encino, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 1 Interventional

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

NCT03058744
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-118 Lotion, HP Monad Lotion, Ultravate Cream, Tazorac Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Anaheim, California • Encino, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 6, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis

NCT05872256
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
0.045% Tazarotene/0.01% Halobetasol Lotion
Drug
Lead sponsor
Dermatology Consulting Services, PLLC
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 6, 2026, 5:19 AM EDT